Chimeric antigen receptor (CAR) T cells are effective for the treatment of therapy-resistant blood cancers but not solid tumors. We used a well-studied mutant c-KIT protein (c-KIT D816V) as a co-stimulatory domain to generate CAR T cells with strong IFNγ signaling that were able to overcome the immunosuppressive microenvironment of solid tumors.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018). A review article summarizing the efficacy and toxicity profile of CAR T cell therapy for hematological malignancies.
Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635–648 (2023). A review article on the current status of CAR T cell design.
Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130–3144 (2016). An original article that details exhaustion in CAR T cells co-stimulated with CD28 and 4-1BB.
Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748–2763 (2021). A CAR T cell clinical trial in solid tumors.
Lennartsson, J. & Ronnstrand, L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol. Rev. 92, 1619–1649 (2012). A review article on c-KIT signaling.
Evans, E. K. et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci. Transl Med. 9, eaao1690 (2017). An original article demonstrating preclinical and clinical evidence of targeted therapy for KIT-mutant disease.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Adusumilli, P. S. et al. c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. Nat. Cancer https://doi.org/10.1038/s43018-023-00573-4 (2023).
Rights and permissions
About this article
Cite this article
A co-stimulatory domain increases CAR T cell therapy efficacy in mice with solid tumors. Nat Cancer 4, 935–936 (2023). https://doi.org/10.1038/s43018-023-00574-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00574-3
